Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (31)
Beatriz Mendes Awni, Marcello Moro Queiroz, Gustavo dos Santos Fernandes & Mauricio Fernando Silva Almeida Ribeiro. 2023. Oncodermatology. Oncodermatology
225
246
.
Adriana Carneiro, Paulina Piairo, Alexandra Teixeira, Dylan Ferreira, Sofia Cotton, Carolina Rodrigues, Alexandre Chícharo, Sara Abalde-Cela, Lúcio Lara Santos, Luís Lima & Lorena Diéguez. (2022) Discriminating Epithelial to Mesenchymal Transition Phenotypes in Circulating Tumor Cells Isolated from Advanced Gastrointestinal Cancer Patients. Cells 11:3, pages 376.
Crossref
Crossref
B. Zarei, M. Moeini Nodeh & O. Arasteh. (2022) Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report. Journal of Oncology Pharmacy Practice, pages 107815522110735.
Crossref
Crossref
Xingkang Wu, Yufang Lu & Xuemei Qin. (2022) Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. Journal of Ethnopharmacology 283, pages 114690.
Crossref
Crossref
Aziza E. Abdelrahman, Doaa Abdelaziz Ibrahim, Ahmed El-Azony, Ahmed A. Alnagar & Amr Ibrahim. (2020) ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy. Cancer Biomarkers 27:2, pages 251-264.
Crossref
Crossref
Yuzhu Hu, Ting Yu, Xiaoxiao Liu, Yihong He, Lihong Deng, Jiajuan Guo, Yuanqi Hua, Ting Luo & Xiang Gao. (2017) Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer. Oncotarget 9:2, pages 2515-2526.
Crossref
Crossref
Javier Garde Noguera, Eloisa Jantus‑Lewintre, Mireia Gil‑Raga, Elena Evgenyeva, Sonia Maci� Escalante, Antonio Llombart‑Cussac & Carlos Camps Herrero. (2017) Role of RAS mutation status as a prognostic factor for�patients with advanced colorectal cancer treated with first‑line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Molecular and Clinical Oncology.
Crossref
Crossref
Amira B. Kassem, Salem Eid Salem, Mohamed E. Abdelrahim, Amira S.A. Said, Ahmad Salahuddin, Marwa Mahmoud Hussein & Abeer A. Bahnassy. (2017) ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. Experimental and Molecular Pathology 102:1, pages 78-85.
Crossref
Crossref
Sanjeev Banerjee & Shivani B. Paruthy. 2017. Glucosinolates. Glucosinolates
339
379
.
Ainsley M. RobinsonVanesa StojanovskaAhmed A. RahmanRachel M. McQuadePaul V. SeniorKulmira Nurgali. (2016) Effects of Oxaliplatin Treatment on the Enteric Glial Cells and Neurons in the Mouse Ileum. Journal of Histochemistry & Cytochemistry 64:9, pages 530-545.
Crossref
Crossref
Sanjeev Banerjee & Shivani B. Paruthy. 2016. Glucosinolates. Glucosinolates
1
41
.
Tara Clancy. (2014) Lynch syndrome: natural history and care of the patient. Gastrointestinal Nursing 12:8, pages 29-33.
Crossref
Crossref
Bettina M. Kaminski, Andreas Weigert, Maria-Christina Scherzberg, Stephanie Ley, Bianca Gilbert, Kerstin Brecht, Bernhard Brüne, Dieter Steinhilber, Jürgen Stein & Sandra Ulrich-Rückert. (2014) Resveratrol-induced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocyte-derived macrophages. Apoptosis 19:7, pages 1136-1147.
Crossref
Crossref
Seung Tae Kim, Kyong Hwa Park, Sang Won Shin & Yeul Hong Kim. (2014) Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?. Cancer Research and Treatment 46:1, pages 48-54.
Crossref
Crossref
V. Heinemann, J.Y. Douillard, M. Ducreux & M. Peeters. (2013) Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action. Cancer Treatment Reviews 39:6, pages 592-601.
Crossref
Crossref
Xi Tao Xu, Zhang Han Dai, Qi Xu, Yu Qi Qiao, Yan Gu, Fang Nie, Ming Ming Zhu, Jin Lu Tong & Zhi Hua Ran. (2013) Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers. Journal of Digestive Diseases 14:6, pages 288-298.
Crossref
Crossref
John M. Furgason & El Mustapha Bahassi. (2013) Targeting DNA repair mechanisms in cancer. Pharmacology & Therapeutics 137:3, pages 298-308.
Crossref
Crossref
Paul J. Hesketh, Pedro Sanz-Altamira, Julie Bushey & Ann M. Hesketh. (2011) Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Supportive Care in Cancer 20:5, pages 1043-1047.
Crossref
Crossref
Xin-Xin Wang, Rong-Ju Sun, Meng Wu, Tao Li, Yong Zhang & Lin Chen. (2012) Differential Protein Expression in EC304 Gastric Cancer Cells Induced by Alphastatin. Asian Pacific Journal of Cancer Prevention 13:4, pages 1667-1674.
Crossref
Crossref
Edward Chu. (2012) An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 11:1, pages 1-13.
Crossref
Crossref
Joseph Della Rocca, Rachel C. Huxford, Erica Comstock‐Duggan & Wenbin Lin. (2011) Polysilsesquioxane Nanoparticles for Targeted Platin‐Based Cancer Chemotherapy by Triggered Release. Angewandte Chemie International Edition 50:44, pages 10330-10334.
Crossref
Crossref
Joseph Della Rocca, Rachel C. Huxford, Erica Comstock‐Duggan & Wenbin Lin. (2011) Polysilsesquioxane Nanoparticles for Targeted Platin‐Based Cancer Chemotherapy by Triggered Release. Angewandte Chemie 123:44, pages 10514-10518.
Crossref
Crossref
Jeffrey S Ross. (2011) Biomarker-based selection of therapy for colorectal cancer. Biomarkers in Medicine 5:3, pages 319-332.
Crossref
Crossref
Bettina M. Kaminski, Andreas Weigert, Bernhard Br?ne, Marco Schumacher, Uwe Wenzel, Dieter Steinhilber, J?rgen Stein & Sandra Ulrich. (2010) Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemotherapy and Pharmacology 67:5, pages 1167-1178.
Crossref
Crossref
Sarah A. Martin, Christopher J. Lord & Alan Ashworth. (2010) Therapeutic Targeting of the DNA Mismatch Repair Pathway. Clinical Cancer Research 16:21, pages 5107-5113.
Crossref
Crossref
Zhen Feng, Yuping Lai, Haifeng Ye, Jing Huang, Xu Guang Xi & Zirong Wu. (2010) Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: A comparative study with clinically used platinum derivatives. Cancer Science 101:11, pages 2476-2482.
Crossref
Crossref
Michael B. Nicholl, Vanita Ahuja, W. Charles Conway, Vu D. Vu, Myung-Shin Sim & Gagandeep Singh. (2010) Small Bowel Adenocarcinoma: Understaged and Undertreated?. Annals of Surgical Oncology 17:10, pages 2728-2732.
Crossref
Crossref
Jeffrey S. Ross, Jorge Torres-Mora, Nikhil Wagle, Timothy A. Jennings & David M. Jones. (2010) Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer. American Journal of Clinical Pathology 134:3, pages 478-490.
Crossref
Crossref
Kimmie Ng & Deborah Schrag. (2010) Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch?. Journal of Clinical Oncology 28:20, pages 3207-3210.
Crossref
Crossref
Madeleine Hewish, Christopher J. Lord, Sarah A. Martin, David Cunningham & Alan Ashworth. (2010) Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature Reviews Clinical Oncology 7:4, pages 197-208.
Crossref
Crossref
J. Iwasaki & S.-i. Nihira. (2009) Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers. Japanese Journal of Clinical Oncology 39:9, pages 543-551.
Crossref
Crossref